# NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer

> **NCT05704829** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **West German Study Group** · enrollment: 402 (estimated)

## Conditions studied

- HER2-positive Early Breast Cancer

## Interventions

- **DRUG:** Trastuzumab deruxtecan
- **DRUG:** Standard-of-Care

## Key facts

- **NCT ID:** NCT05704829
- **Lead sponsor:** West German Study Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-02-05
- **Primary completion:** 2025-06-18
- **Final completion:** 2029-06
- **Target enrollment:** 402 (ESTIMATED)
- **Last updated:** 2025-11-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05704829

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05704829, "NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05704829. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*